Laboratory and office facility
Sartorius Stedim Cellca is developing the Cell Culture Technology Center (CCTC) in Science Park III in Germany, with an estimated investment of €30m ($35.2m).
Sartorius Stedim Cellca is a subsidiary of Sartorius Stedim Biotech that has established innovative cell line development technology Cellca CHO Expression Platform.
The company held the groundbreaking ceremony for the facility in September 2017 to mark the start of construction. The new facility is expected to be completed by the end of 2019.
Science Park III is accessible through different transportation routes as it lies between Stuttgart and Munich.
Moving operations to this new facility will make it easier and more convenient for international customers to visit the company. The relocation will also place the CCTC closer to universities and research institutes that are in the vicinity of Ulm city.
The new centre is being built on 6,000m² of land bought by Sartorius in November 2016.
The company is currently operating from a rented building in Laupheim with 90 employees. Rapid growth in business has necessitated a bigger space for the growing employee base and production facilities.
The new facility will include a laboratory and office space and will double Sartorius’ total space.
Sartorius Stedim Cellca devised a unique cell line development technology platform for protein production of biopharmaceuticals in Chinese hamster ovary (CHO) cells.
The platform helps provide stable cell lines with simple feed-batch processes for the biopharmaceutical industry. It consists of an expression vector, a host cell line, a CHO media system, and an upstream process design.
The Cellca CHO expression platform helps generate cell cultures from the DNA stage to the RCB stage within four months. It has developed 3g/L protein titers in 12-14 day standard feed-batch process.
The processes can be transferred and scaled-up to 1,000l range bioreactors using the platform, and more than 40 projects have successfully been completed.
Headquartered in France, Sartorius Stedim Biotech is an international supplier of products and services to the pharmaceutical industry.
The company serves as a total solution provider. Its portfolio covers various aspects of biopharmaceutical manufacturing.
The firm employed 4,700 staff members and generated €1.05bn ($1.1bn) in revenue in 2016.
Cellca was acquired by Sartorius Stedim Biotech Group in 2015 to become Sartorius Stedim Cellca. The new entity develops cell lines and protein production processes, as well as licenses technologies for protein production and offers media to develop cell culture.
The proteins are produced using living cells under controlled conditions and are used as the basis for the development and manufacture of medications.
Sartorius plans to expand its workforce by employing more than 120 employees in the future.
Contract development and manufacturing organisation (CDMO) Sai Life Sciences inaugurated its new research and technology (R&T) centre in Hyderabad, India…
Wearable drug delivery devices manufacturer Sorrel Medical opened a new manufacturing facility in Israel in July 2020. The facility will…
Neopharma opened a pharmaceutical plant in Abu Dhabi, United Arab Emirates, in July 2003. The plant then entered a three-month…